These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 9532517

  • 1. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
    Zanchetti A.
    J Hypertens Suppl; 1997 Dec; 15(7):S21-5. PubMed ID: 9532517
    [Abstract] [Full Text] [Related]

  • 2. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group.
    Fogari R, Ambrosoli S, Corradi L, Degli Esposti E, Mos L, Nami R, Nicrosini F, Pessina AC, Salvetti A, Vaccarella A, Zanchetti A, Martin A, Reeves RA.
    J Hypertens; 1997 Dec; 15(12 Pt 1):1511-8. PubMed ID: 9431859
    [Abstract] [Full Text] [Related]

  • 3. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL.
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [Abstract] [Full Text] [Related]

  • 4. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M.
    J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
    [Abstract] [Full Text] [Related]

  • 5. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A, Calvo C, Sobrino J, Gómez E, López-Paz JE, Sierra C, Bragulat E, de la Sierra A.
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [Abstract] [Full Text] [Related]

  • 6. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
    Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B.
    Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
    [Abstract] [Full Text] [Related]

  • 7. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
    Howe P, Phillips P, Saini R, Kassler-Taub K.
    Clin Exp Hypertens; 1999 Nov; 21(8):1373-96. PubMed ID: 10574419
    [Abstract] [Full Text] [Related]

  • 8. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
    Weber MA, Neutel JM, Smith DH.
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
    [Abstract] [Full Text] [Related]

  • 9. Blood pressure effects of the angiotensin II receptor blocker, losartan.
    Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB.
    Arch Intern Med; 1995 Feb 27; 155(4):405-11. PubMed ID: 7848024
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H, Yang HM, Lee HY, Kim JJ, Choi DJ, Seung KB, Jeon ES, Ha JW, Rim SJ, Park JB, Shin JH, Oh BH.
    Clin Ther; 2012 Jun 27; 34(6):1273-89. PubMed ID: 22608107
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
    Kawano Y, Sato Y, Yoshinaga K.
    Hypertens Res; 2008 Sep 27; 31(9):1753-63. PubMed ID: 18971554
    [Abstract] [Full Text] [Related]

  • 12. [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
    Vaïsse B, Ghobrial H, Vaur L, Poncelet P, Asmar R, Herpin D, Mallion JM.
    Arch Mal Coeur Vaiss; 2001 Aug 27; 94(8):907-12. PubMed ID: 11575229
    [Abstract] [Full Text] [Related]

  • 13. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L.
    J Hypertens Suppl; 1997 Dec 27; 15(7):S15-20. PubMed ID: 9532516
    [Abstract] [Full Text] [Related]

  • 14. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML, de Cristofaro A, Rossi M, Baiano A, Cardace P, Albanese L, Vigorito C.
    J Cardiovasc Pharmacol; 2001 Sep 27; 38(3):482-9. PubMed ID: 11486253
    [Abstract] [Full Text] [Related]

  • 15. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB, Lacourciere Y, Davidai G.
    Am J Hypertens; 2004 Apr 27; 17(4):347-53. PubMed ID: 15062889
    [Abstract] [Full Text] [Related]

  • 16. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.
    Clin Ther; 2004 Sep 27; 26(9):1436-45. PubMed ID: 15531006
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
    Byyny RL.
    Blood Press Suppl; 1996 Sep 27; 2():71-7. PubMed ID: 8913544
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
    de la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J.
    J Hum Hypertens; 2004 Mar 27; 18(3):215-22. PubMed ID: 14973517
    [Abstract] [Full Text] [Related]

  • 19. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ.
    J Hypertens Suppl; 1997 Dec 27; 15(7):S27-33. PubMed ID: 9532518
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
    Ulusoy S, Ozkan G, Konca C, Kaynar K.
    Hypertens Res; 2012 Nov 27; 35(11):1111-7. PubMed ID: 22786565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.